Recent advancement in drug development of nitro(NO2)-heterocyclic compounds as lead scaffolds for the treatment of Mycobacterium tuberculosis
Nenhuma Miniatura disponível
Data
2022-01-01
Autores
Scarim, Cauê Benito
Pavan, Fernando Rogério [UNESP]
Título da Revista
ISSN da Revista
Título de Volume
Editor
Resumo
Tuberculosis (TB) is an infectious disease caused predominantly by Mycobacterium tuberculosis (Mtb). It was responsible for approximately 1.4 million deaths worldwide in 2019. The lack of new drugs to treat drug-resistant strains is a principal factor for the slow rise in TB infections. Our aim is to aid the development of new TB treatments by describing improvements (last decade, 2011–2021) to nitro(NO2)-based compounds that have shown activity or pharmacological properties (e.g., anti-proliferative, anti-kinetoplastid) against Mtb. For all compounds, we have included final correlations of minimum inhibitory concentrations against Mtb (H37Rv).
Descrição
Palavras-chave
Como citar
Drug Development Research.